Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
$0.50
-2.6%
$0.52
$0.37
▼
$1.54
$14.02M1.05273,591 shs140,759 shs
Gelteq Limited stock logo
GELS
Gelteq
$0.28
+3.9%
$0.49
$0.26
▼
$2.01
$3.11M-0.3774,865 shs10,956 shs
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
$1.42
-6.6%
$2.75
$1.33
▼
$12.42
$12.29M0.51106,673 shs78,932 shs
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
$0.95
-9.0%
$1.16
$0.77
▼
$5.69
$13.90M0.37362,579 shs76,347 shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
-2.64%-6.61%+19.09%-17.16%-50.28%
Gelteq Limited stock logo
GELS
Gelteq
+3.93%-26.31%-37.37%-50.14%-69.24%
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
-6.58%-20.22%-41.56%-58.72%-77.50%
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
-9.03%-18.09%-4.63%-49.13%-75.93%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
$0.50
-2.6%
$0.52
$0.37
▼
$1.54
$14.02M1.05273,591 shs140,759 shs
Gelteq Limited stock logo
GELS
Gelteq
$0.28
+3.9%
$0.49
$0.26
▼
$2.01
$3.11M-0.3774,865 shs10,956 shs
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
$1.42
-6.6%
$2.75
$1.33
▼
$12.42
$12.29M0.51106,673 shs78,932 shs
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
$0.95
-9.0%
$1.16
$0.77
▼
$5.69
$13.90M0.37362,579 shs76,347 shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
-2.64%-6.61%+19.09%-17.16%-50.28%
Gelteq Limited stock logo
GELS
Gelteq
+3.93%-26.31%-37.37%-50.14%-69.24%
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
-6.58%-20.22%-41.56%-58.72%-77.50%
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
-9.03%-18.09%-4.63%-49.13%-75.93%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
2.40
Hold$6.001,106.76% Upside
Gelteq Limited stock logo
GELS
Gelteq
1.00
SellN/AN/A
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
2.00
Hold$8.00463.38% Upside
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
2.88
Moderate Buy$9.40893.55% Upside

Current Analyst Ratings Breakdown

Latest GELS, TVRD, CTXR, and QNTM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/18/2026
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
UpgradeSell (E+) ➝ Sell (D-)
11/2/2026
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
DowngradeSell (D-) ➝ Sell (E+)
10/20/2026
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
Initiated CoverageBuy
10/2/2026
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
Reiterated RatingSell (E+)
9/22/2026
Gelteq Limited stock logo
GELS
Gelteq
Reiterated RatingSell (E+)
9/21/2026
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
Reiterated RatingSell (E+)
9/8/2026
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
UpgradeStrong-Buy
8/31/2026
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
Initiated CoverageBuy$8.00
8/21/2026
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
N/AN/AN/AN/A$4.29 per shareN/A
Gelteq Limited stock logo
GELS
Gelteq
$240K13.46N/AN/A$1.08 per share0.26
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
N/AN/AN/AN/A$1.21 per shareN/A
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
$7.14M1.77N/AN/A$1.16 per share0.82
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
-$37.43M-$1.67N/AN/AN/AN/A-59.57%-34.47%12/22/2026 (Estimated)
Gelteq Limited stock logo
GELS
Gelteq
-$4.30MN/AN/AN/AN/AN/AN/AN/AN/A
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
-$26.17M-$4.30N/AN/AN/AN/A-412.03%-139.32%N/A
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
-$18.21M-$2.68N/AN/AN/AN/A-179.87%-107.78%N/A

Latest GELS, TVRD, CTXR, and QNTM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/16/2026Q4 2026
Gelteq Limited stock logo
GELS
Gelteq
N/A-$0.64N/A-$0.64N/AN/A
11/13/2026Q3 2026
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
-$0.51-$0.48+$0.03-$0.48N/AN/A
11/12/2026Q3 2026
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
-$0.50-$0.06+$0.44-$0.06N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
N/AN/AN/AN/AN/A
Gelteq Limited stock logo
GELS
Gelteq
N/AN/AN/AN/AN/A
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
N/AN/AN/AN/AN/A
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
0.08
0.84
0.40
Gelteq Limited stock logo
GELS
Gelteq
N/AN/AN/A
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
N/A
1.72
1.19
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
N/A
2.86
1.87

Institutional Ownership

CompanyInstitutional Ownership
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
16.88%
Gelteq Limited stock logo
GELS
Gelteq
N/A
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
1.24%
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
44.66%

Insider Ownership

CompanyInsider Ownership
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
4.99%
Gelteq Limited stock logo
GELS
Gelteq
N/A
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
8.53%
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
7.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
2327.45 million26.08 millionOptionable
Gelteq Limited stock logo
GELS
Gelteq
1811.51 millionN/AN/A
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
178.09 million7.40 millionN/A
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
1213.36 million12.37 millionOptionable

Recent News About These Companies

HC Wainwright Has Positive Forecast for TVRD FY2026 Earnings
Chardan Starts Tvardi Therapeutics Inc (TVRD) at Buy

New MarketBeat Followers Over Time

Media Sentiment Over Time

Citius Pharmaceuticals stock logo

Citius Pharmaceuticals NASDAQ:CTXR

$0.50 -0.01 (-2.64%)
Closing price 11/19/2026 04:00 PM Eastern
Extended Trading
$0.49 -0.01 (-2.25%)
As of 11/19/2026 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Gelteq stock logo

Gelteq NASDAQ:GELS

$0.28 +0.01 (+3.93%)
Closing price 11/19/2026 03:59 PM Eastern
Extended Trading
$0.28 0.00 (-0.57%)
As of 11/19/2026 04:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Gelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.

Quantum Biopharma stock logo

Quantum Biopharma NASDAQ:QNTM

$1.42 -0.10 (-6.58%)
Closing price 11/19/2026 04:00 PM Eastern
Extended Trading
$1.43 +0.01 (+0.42%)
As of 11/19/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

Tvardi Therapeutics stock logo

Tvardi Therapeutics NASDAQ:TVRD

$0.95 -0.09 (-9.03%)
Closing price 11/19/2026 04:00 PM Eastern
Extended Trading
$0.96 +0.01 (+1.47%)
As of 11/19/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.